Vaccine composition comprising 5′-cap modified RNA

US9295717B2 · kind B2 · utility

Assignees

• BioNTech AG · DE
• TRON—Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz · DE
• UNIWERSYTET WARSZAWSKI · PL

Inventors

• Ugur Sahin · Mainz, DE
• Andreas Kuhn · Mainz, DE
• Edward Darzynkiewicz · Białystok, PL
• Jacek Jemielity · Warszawa, PL
• Joanna Kowalska · Radom, PL

Key dates

• Filing date: Aug 3, 2010
• Grant date: Mar 29, 2016
• Expiry date: Aug 27, 2032

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K2039/53
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to modification of RNA with 5′-cap analogs of Formula (1):wherein R1-R6 and n are as described herein, in order to improve the stability and increase the expression of said RNA, in particular in immature antigen presenting cells. The present invention provides a vaccine composition comprising said stabilized RNA, immature antigen presenting cells comprising said stabilized RNA, and methods for stimulating and/or activating immune effector cells and for inducing an immune response in an individual using said stabilized RNA.